194785-92-7

Upstream product

• 24424-99-5 di-tert-butyl dicarbonate 
• 194785-91-6 C₆₅H₇₃N₅O₂₁S 
• 98-59-9 p-toluenesulfonyl chloride 
• 172950-21-9 di-tert-butyl ((1S,3R,4S,5S,6R)-4-(((2S,3R,4S,5S,6R)-4-((tert-butoxycarbonyl)amino)-3,5-dihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)oxy)-6-(((2R,3R,5S,6R)-3-((tert-butoxycarbonyl)amino)-6-(((tert-butoxycarbonyl)methyl)-5-hydroxytetrahydro-2H-pyran-2-yl)oxy)-5-hydroxycyclohexane-1,3-diyl)dicarbamate) 

Downstream Products

• 194785-93-8 6''-β-mercaptoethylether-Boc5-tobramycin 
• 194785-94-9 C₅₂H₈₈N₆O₁₉S₃ 
• 519171-28-9 di-tert-butyl (((1S,3R,4S,5S,6R)-4-(((2R,3R,4S,5S,6R)-6-(azidomethyl)-4-((tertbutoxycarbonyl)amino)-3,5-dihydroxytetrahydro-2H-pyran-2-yl)oxy)-6-(((2R,3R,5S,6R)-3-((tert-butoxycarbonyl)amino)-methyl)-5-hydroxytetrahydro-2H-pyran-2-yl)oxy)-5-hydroxycyclohexane-1,3-diyl)dicarbamate 

Relevant academic research and scientific papers

MULTIFUNCTIONAL ANTIBIOTIC-PEPTIDE CONJUGATES: SYNTHESIS AND ANTIMICROBIAL ACTIVITIES

The invention relates to multi-functional antibiotic agents formed from antibiotics conjugated to microbial membrane disrupting peptides. These antibiotic-peptide conjugates are designed so that the conjugate simultaneously functions as a membrane disrupt

Dimeric aminoglycosides: Design, synthesis and RNA binding

The design and synthesis of symmetrical and non-symmetrical dimeric aminoglycosides derived from kanamycin A, tobramycin, and neomycin B are described. The covalently-linked dimeric aminoglycosides show enhanced activity as ribozyme inhibitors when compared to their natural counterparts.